Kubota Pharmaceutical Holdings Co., Ltd.
Tokyo Stock Exchange 4596.T
Kubota Pharmaceutical Holdings Co., Ltd. Dividend Per Share for the year ending December 31, 2023: USD -0.00
Kubota Pharmaceutical Holdings Co., Ltd. Dividend Per Share is USD -0.00 for the year ending December 31, 2023, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.
-
Kubota Pharmaceutical Holdings Co., Ltd. Dividend Per Share for the year ending December 31, 2022 was USD -0.00, a 0.00% change year over year.
-
Kubota Pharmaceutical Holdings Co., Ltd. Dividend Per Share for the year ending December 31, 2021 was USD -0.00, a 0.00% change year over year.
-
Kubota Pharmaceutical Holdings Co., Ltd. Dividend Per Share for the year ending December 31, 2020 was USD -0.00, a 0.00% change year over year.
-
Kubota Pharmaceutical Holdings Co., Ltd. Dividend Per Share for the year ending December 31, 2019 was USD -0.00.
Key data
| Date | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) |
|---|
Market news
Loading...
Don’t Miss A Beat
Tokyo Stock Exchange: 4596.T
| CEO | Dr. Ryo Kubota M.D., Ph.D. |
| IPO Date | Dec. 6, 2016 |
| Location | Japan |
| Headquarters | 3-7-1 Kasumigaseki |
| Employees | 12 |
| Sector | Health Care |
| Industries | |
Description
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Key trends
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email